Results 21 to 30 of about 6,036 (190)

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy. [PDF]

Adv Sci (Weinh)
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Lee J, Lim CG, Vairaprakash P, Kim JM, Kim J, Park JY, Hahn KM, Shim H, Choi HW, Ulmer TS, Hong SJ, Kim C.   +11 more
europepmc   +2 more sources

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. [PDF]

Allergy
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Cortellini G, Nakonechna A, Barbaud A, Bavbek S, Calogiuri G, Doña I, Kvedariene V, Laguna Martinez JJ, Liberati S, Pagani M, Romano A.   +10 more
europepmc   +2 more sources

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken, Arnoud W. J. van 't Hof, Jurriën M. ten Berg, Dean J. Kereiakes, Barry S. Coller   +4 more
doaj   +1 more source

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

Trials, 2009
Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L, Fokkema Marieke L, Kampinga Marthe A, de Smet Bart JGL, Tan Eng S, van den Heuvel Ad FM, Zijlstra Felix   +6 more
doaj   +1 more source

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

Platelets, 2022
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of ...
Pablo Revilla-Martí, Jose A. Linares-Vicente, Ana Martínez Labuena, Octavio Jiménez Melo, Paula Morlanes Gracia, Daniel Meseguer González, Antonela Lukic, Borja Simó Sánchez, Jose R. Ruiz Arroyo   +8 more
doaj   +1 more source

Antiphospholipid syndrome and acute myocardial infarction: Treatment with thrombectomy and abciximab

Revista Portuguesa de Cardiologia, 2014
Antiphospholipid syndrome (APS) is an autoimmune coagulation disorder that manifests clinically as venous and arterial thrombosis, and may affect any tissue or organ. Coronary artery involvement, however, is very rare.
Vicens Martí, Filipe Seixo, Miguel Santaló, Antonio Serra   +3 more
doaj   +1 more source

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

Journal of Interventional Cardiology, 2022
Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background.
Nan Bai, Ying Niu, Ying Ma, Yao-Sheng Shang, Peng-Yu Zhong, Zhi-Lu Wang   +5 more
doaj   +1 more source

FLOW DIVERTER DEVICE IN THE ACUTE SETTING OF RUPTURED BLISTER LIKE ANEURYSM: A CASE REPORT [PDF]

Euromediterranean Biomedical Journal, 2021
Blister-like aneurysms (BLA) are a rare half-dome-shaped aneurysm, with a broad-based appearance, originating more often from a non-branching site of the supraclinoid internal carotid artery (ICA).
Cesare Gaglaiardo
doaj   +1 more source

Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

BMC Cardiovascular Disorders, 2017
Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández, Mario Sadaba Sagredo, Miren Telleria Arrieta, Federico Gimeno de Carlos, Elena Sanchez Lacuesta, Juan A. Bullones Ramírez, Javier Pineda Rocamora, Victoria Martin Yuste, Tamara Garcia Camarero, Mariano Larman, Jose R. Rumoroso   +10 more
doaj   +1 more source

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

, 2008
Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI).
N. d. Cesare, R. Moreno, S. Colangelo, M. Valgimigli, G. Parrinello, A. E. Rodriguez, M. E. of Single High Dose Bolus Tirofiban vs Abciximab With Sirolimus Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study Investigators, G. Percoco, M. S. Nazzaro, VASSANELLI, Corrado, F. Prati, R. Ferrari, L. Bolognese, G. Pasquetto, T. Piva, M. Ferrario, I. Sheiban, G. Campo   +17 more
core   +2 more sources